Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives

Arbutus Biopharma FY 2025 Earnings Snapshot

Arbutus Biopharma (ABUS) has turned in a mixed FY 2025 readout so far, with Q3 total revenue at US$0.5 million and a basic EPS loss of US$0.04, alongside trailing twelve month revenue of US$14.6 million and a basic EPS loss of US$0.22. Over recent quarters, the company has reported revenue in a range between US$0.5 million and US$10.7 million per quarter, while quarterly basic EPS has ranged from a loss of US$0.13 to a profit of US$0.01. This gives investors a clear view of how volatile margins remain as the pipeline advances. For anyone monitoring the company, an important consideration is how those margins evolve as Arbutus Biopharma continues to invest in its Phase I and Phase II programs.

See our full analysis for Arbutus Biopharma.

With the headline numbers on the table, the next step is to set these results against the main stories investors follow about Arbutus Biopharma and assess which narratives still fit and which are starting to look out of date.

Curious how numbers become stories that shape markets? Explore Community Narratives

Losses Narrow On Trailing Basis

• On a trailing twelve month view, Arbutus Biopharma reported total revenue of US$14.6 million and a net loss of US$42.3 million, with basic EPS at a loss of US$0.22.
• What stands out for a bullish read is that reported losses have been shrinking at about 6.3% per year over the past five years. However, the latest trailing twelve month net loss of US$42.3 million keeps the company clearly unprofitable, so any optimistic case has to balance the improving loss trend with the reality that the business is still a long way from break even.
  • Supporters may point to the move from a trailing twelve month loss of US$77.1 million in 2024 Q2 to US$42.3 million in 2025 Q3 as evidence that the earnings profile is improving in absolute dollar terms.
  • At the same time, quarterly results remain uneven, with 2025 Q2 net income of US$2.5 million turning back into a US$7.7 million loss in 2025 Q3, which shows that the path of that bullish trend is not smooth.

Investors weighing that improving loss trend against the still sizeable trailing twelve month deficit can get more context from community views on Arbutus Biopharma by checking how different narratives line up with these numbers 📊 Read the what the Community is saying about Arbutus Biopharma..

High P/B Multiple At Around 11x

• The shares trade on a P/B ratio of about 11x, compared with roughly 2.5x for the broader US biotech group and 4.9x for peers, even though Arbutus Biopharma is loss making on a trailing twelve month basis.
• Critics highlight that this bearish valuation concern is grounded in the combination of a high 11x P/B multiple and a trailing twelve month net loss of US$42.3 million. This means the balance sheet is carrying a sizeable book value while current earnings do not yet support that premium.
  • The contrast between an 11x P/B and sector levels closer to 2.5x suggests that even modest negative news around the US$42.3 million loss could have an outsized effect on sentiment.
  • With the company not expected to reach profitability within the next three years based on the risk summary, skeptics focus on whether the current book value can justify that premium without visible earnings support.

Q2 Profitability Was Brief

• Within the FY 2025 year to date, Q2 stands out with revenue of US$10.7 million and net income of US$2.5 million, while Q1 and Q3 both showed losses, at US$24.5 million and US$7.7 million respectively.
• What is surprising for anyone leaning bullish is that the single profitable quarter in 2025 Q2 did not carry through into 2025 Q3, where revenue dropped back to US$0.5 million and the company returned to a quarterly loss. This mixed pattern keeps the focus on how dependent results may be on specific revenue events rather than on a steady earnings base.
  • The swing from a basic EPS profit of US$0.01 in the best quarter of the recent history to a loss of US$0.13 in weaker periods underlines how sensitive EPS has been to quarter by quarter revenue changes.
  • Over the last six reported quarters, net income figures have ranged from a loss of US$24.5 million to a profit of US$2.5 million, which shows how variable the earnings profile has been during the current development phase.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Arbutus Biopharma's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

These numbers raise as many questions as they answer, so if you are weighing the mixed signals here, move quickly to examine both sides of the story and weigh the 1 key reward and 1 important warning sign

See What Else Is Out There

Arbutus Biopharma combines an 11x P/B multiple with uneven quarterly earnings and a trailing twelve month net loss of US$42.3 million, which may keep risk elevated for now.

If that mix of volatility and premium pricing feels uncomfortable, you can compare it with companies that score better on resilience and fundamentals using the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com